Cell surface expression of the multidrug resistance P-glycoprotein (P-170) as detected by monoclonal antibody MRK-16 in pediatric acute myeloid leukemia fails to define a poor prognostic group: A report from the childrens cancer group

E. L. Sievers, F. O. Smith, W. G. Woods, J. W. Lee, W. A. Bleyer, C. L. Willman, I. D. Bernstein

Research output: Contribution to journalArticlepeer-review

Abstract

Expression of the multidrug resistance (MDR-1) gene product, P-glycoprotein (P-170), and the stem cell antigen, CD34, at diagnosis were determined using monoclonal antibodies (MoAbs) MRK-16 and 12.8, respectively, in 130 pediatric acute myeloid leukemia (AML) patients entered onto Childrens Cancer Group (CCG) study CCG-2891. Fluorescein isothiocyanate (FITC) as a second step reagent was employed for the measurement of P-170 expression since it is commonly used in clinical laboratories. Nine of 30 (30%) infant (<1 year of age) de novo specimens expressed P-170 at levels ≥20% of control cells. In contrast, eight of 100 (8%) AML samples from older children (≥1 year of age) expressed the multidrug resistance surface protein at diagnosis. With the exception of one infant, all de novo samples that expressed P-170 also expressed CD34. Pediatric patients of any age with positive P-170 expression using MoAb MRK-16 with a FITC-conjugated second step reagent fared no worse than remaining patients treated on the same treatment with regard to induction failure, incidence of relapse, event-free survival, or overall survival. Further investigation is necessary to determine whether P-170 assay systems with greater sensitivity will distinguish pediatric AML patients with poor prognosis.

Original languageEnglish (US)
Pages (from-to)2042-2048
Number of pages7
JournalLeukemia
Volume9
Issue number12
StatePublished - Dec 1995

Keywords

  • Acute myelogenous leukemia
  • Flow cytometry
  • MDR
  • Multidrug resistance
  • P-glycoprotein
  • Treatment outcome

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Cell surface expression of the multidrug resistance P-glycoprotein (P-170) as detected by monoclonal antibody MRK-16 in pediatric acute myeloid leukemia fails to define a poor prognostic group: A report from the childrens cancer group'. Together they form a unique fingerprint.

Cite this